Roxana Mansour Ghanaiee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roxana Mansour Ghanaiee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abdollah Karimi
Pediatric Infections Research Center, Research Institute for Children's Health Shahid Beheshti University of Medical Sciences Tehran Iran
2 shared publications - Seyedeh Mahsan Hoseini-Alfatemi
Pediatric Infections Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ahmad Reza Shamshiri
Research Center for Caries Prevention, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Amirata Fakhfouri
Iranian Research Center for HIV/AIDS Tehran University of Medical Sciences Tehran Iran
1 shared publication - Arian Ashnaei
Pediatric Infections Research Center, Research Institute for Children's Health Shahid Beheshti University of Medical Sciences Tehran Iran
1 shared publication - Azadeh Jafrasteh
Department of Pediatrics, School of Medicine Lorestan University of Medical Sciences Khorramabad Iran
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Clinical Phenotype and Outcomes of Multisystem Inflammatory Syndrome in Children According to SARS‐CoV‐2 Laboratory Status During 2020–2021: A Retrospective Observational Study
Background and Aims: Multisystem inflammatory syndrome in children (MIS‐C) is a post‐infectious inflammatory condition associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that can affect multiple organ systems. Data comparing clinical features and outcomes between MIS‐C patients with and without laboratory evidence of coronavirus disease 2019 (COVID‐19) remain limited. Methods: This retrospective observational study was conducted at Mofid Children's Hospital, a pediatric referral center in Tehran, Iran, between March 2020 and July 2021. Children diagnosed with MIS‐C based on World Health Organization (WHO) criteria were included and classified into groups with and without laboratory evidence of SARS‐CoV‐2 infection according to PCR and/or IgG serology results. Demographic data, clinical manifestations, laboratory and imaging findings, treatments, and outcomes were compared between the groups using univariate and multivariable analyses. A p ‐value < 0.05 was considered statistically significant. Results: A total of 121 patients with MIS‐C were included, of whom 44 (36.4%) had laboratory evidence of SARS‐CoV‐2 infection. The mean age was 4.74 ± 3.99 years, and 61.2% were male. ICU admission occurred in 21.5% and mortality was 2.5%. In univariate analysis, fever during the first 24 h of hospitalization and antiviral use were more frequent in the group with laboratory evidence, whereas conjunctivitis and elevated C‐reactive protein levels were more common among the group without laboratory evidence; however, CRP did not differ significantly between groups when analyzed as a continuous variable. In multivariable analysis, fever during the first 24 h of hospitalization was the only variable associated with laboratory evidence of SARS‐CoV‐2 infection (aOR 2.57; 95% CI 1.05–6.30; p = 0.040). Conclusion: MIS‐C presents with broad and largely overlapping clinical, laboratory, and imaging features regardless of SARS‐CoV‐2 laboratory status, and the few observed differences were exploratory and of limited discriminative value. These findings highlight the importance of considering MIS‐C even in the absence of laboratory confirmation of SARS‐CoV‐2 infection.
- 5 November 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Open AccessClinical Phenotype and Outcomes of Multisystem Inflammatory Syndrome in Children According to SARS‐CoV‐2 Laboratory Status During 2020–2021: A Retrospective Observational Study
Background and Aims: Multisystem inflammatory syndrome in children (MIS‐C) is a post‐infectious inflammatory condition associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that can affect multiple organ systems. Data comparing clinical features and outcomes between MIS‐C patients with and without laboratory evidence of coronavirus disease 2019 (COVID‐19) remain limited. Methods: This retrospective observational study was conducted at Mofid Children's Hospital, a pediatric referral center in Tehran, Iran, between March 2020 and July 2021. Children diagnosed with MIS‐C based on World Health Organization (WHO) criteria were included and classified into groups with and without laboratory evidence of SARS‐CoV‐2 infection according to PCR and/or IgG serology results. Demographic data, clinical manifestations, laboratory and imaging findings, treatments, and outcomes were compared between the groups using univariate and multivariable analyses. A p ‐value < 0.05 was considered statistically significant. Results: A total of 121 patients with MIS‐C were included, of whom 44 (36.4%) had laboratory evidence of SARS‐CoV‐2 infection. The mean age was 4.74 ± 3.99 years, and 61.2% were male. ICU admission occurred in 21.5% and mortality was 2.5%. In univariate analysis, fever during the first 24 h of hospitalization and antiviral use were more frequent in the group with laboratory evidence, whereas conjunctivitis and elevated C‐reactive protein levels were more common among the group without laboratory evidence; however, CRP did not differ significantly between groups when analyzed as a continuous variable. In multivariable analysis, fever during the first 24 h of hospitalization was the only variable associated with laboratory evidence of SARS‐CoV‐2 infection (aOR 2.57; 95% CI 1.05–6.30; p = 0.040). Conclusion: MIS‐C presents with broad and largely overlapping clinical, laboratory, and imaging features regardless of SARS‐CoV‐2 laboratory status, and the few observed differences were exploratory and of limited discriminative value. These findings highlight the importance of considering MIS‐C even in the absence of laboratory confirmation of SARS‐CoV‐2 infection.
- 30 July 2026
- Published by Maad Rayan Publishing Company in Epidemiology and Health System Journal
- Vol. 13 (2) , 98-103
Investigating BCG Vaccine-Related Adverse Events Following BCG Vaccination in Children Referred to Healthcare Centers in Tehran and Alborz, Iran
Introduction: Bacillus Calmette-Guérin (BCG) vaccination is routinely administered at birth to prevent severe tuberculosis. Although BCG is generally safe, adverse events may occur. Therefore, this study aimed to describe reported adverse events following BCG vaccination among children referred to healthcare centers in Tehran and Alborz Provinces during one year of follow-up. Methods: This registry-based prospective descriptive cohort study included 976 children enrolled between September 2022 and February 2024. Participants attending healthcare centers in Tehran and Alborz were followed for one year, with assessments every four months. To this end, parent-reported and clinically documented adverse events were recorded using Rabbit. Finally, SPSS 23 was used for data analysis. Results: Among 976 participants, 492 (50.4%) were boys and 484 (49.6%) were girls. Diarrhea (4.20%, n = 41), skin rash (2.15%, n = 21), and fever (1.74%, n = 17) were the most frequently reported adverse events. However, decreased milk intake (1.02%, n = 10) and lymphadenopathy (0.61%, n = 6) were less common. All reported events were transient and resolved without hospitalization. Ultimately, no cases of disseminated BCG infection, osteitis, or vaccine-related mortality were observed during the follow-up. Conclusion: Reported adverse events during the follow-up were uncommon, mild, and self-limited. Given that this descriptive study lacked diagnostic confirmation and a comparison group, no causal relationship could be established between the reported events and BCG vaccination, requiring larger studies to evaluate rare BCG-related complications.
- 30 July 2026
- Published by Maad Rayan Publishing Company in Epidemiology and Health System Journal
- Vol. 13 (2) , 98-103
Investigating BCG Vaccine-Related Adverse Events Following BCG Vaccination in Children Referred to Healthcare Centers in Tehran and Alborz, Iran
Introduction: Bacillus Calmette-Guérin (BCG) vaccination is routinely administered at birth to prevent severe tuberculosis. Although BCG is generally safe, adverse events may occur. Therefore, this study aimed to describe reported adverse events following BCG vaccination among children referred to healthcare centers in Tehran and Alborz Provinces during one year of follow-up. Methods: This registry-based prospective descriptive cohort study included 976 children enrolled between September 2022 and February 2024. Participants attending healthcare centers in Tehran and Alborz were followed for one year, with assessments every four months. To this end, parent-reported and clinically documented adverse events were recorded using Rabbit. Finally, SPSS 23 was used for data analysis. Results: Among 976 participants, 492 (50.4%) were boys and 484 (49.6%) were girls. Diarrhea (4.20%, n = 41), skin rash (2.15%, n = 21), and fever (1.74%, n = 17) were the most frequently reported adverse events. However, decreased milk intake (1.02%, n = 10) and lymphadenopathy (0.61%, n = 6) were less common. All reported events were transient and resolved without hospitalization. Ultimately, no cases of disseminated BCG infection, osteitis, or vaccine-related mortality were observed during the follow-up. Conclusion: Reported adverse events during the follow-up were uncommon, mild, and self-limited. Given that this descriptive study lacked diagnostic confirmation and a comparison group, no causal relationship could be established between the reported events and BCG vaccination, requiring larger studies to evaluate rare BCG-related complications.